Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Anixa Biosciences, Inc.NASDAQ: ANIX
Stock-Based Compensation · Q2 FY2026 · quarter ended Apr 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $665K fell 30.9% year over year, ahead of the -44.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.4% from the prior quarter. Over 3 fiscal years it compounded at -15.0% a year.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -30.9% holds above the trailing-twelve-month pace of -44.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.68M USD
- Year-over-year change
- -16.7%
- 4-year CAGR
- -16.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 3.68M | -16.7% |
| FY2024 | 2024-10-31 | 4.42M | -0.0% |
| FY2023 | 2023-10-31 | 4.42M | -26.3% |
| FY2022 | 2022-10-31 | 6M | -20.0% |
| FY2021 | 2021-10-31 | 7.5M | — |
Stock-Based Compensation vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's LTM Apr 2026 stock-based compensation of $2.26M is the 9th largest of the 10 companies compared; the peer median is $5M.
- Its year-over-year change of -44.4% is the 6th highest of 9, against a peer median of -29.4%.
- Over three fiscal years its annual growth of -15.0% compares with a peer median of +7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $9.77M | +1.5% | +47.6% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6.28M | +111.2% | +109.9% | — |
| LTM Mar 2026 | $5M | — | +208.8% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Mar 2026 | $3.88M | -47.0% | -22.0% | 7.1% | |
| LTM Mar 2026 | $3.06M | -44.1% | -45.0% | — | |
| LTM Apr 2026 | $2.26M | -44.4% | -15.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | +7.0% | — | |
| Peer median (excluding ANIX) | $5M | -29.4% | +7.0% | 20.6% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Depreciation & Amortization | 60K | 42K | 46K | 37K | (107K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.5M | 6M | 4.42M | 4.42M | 3.68M |
| Change in Working Capital | 78K | 485K | (1.06M) | 526K | 152K |
| Accounts Receivables | 0 | (29K) | (224K) | 97K | 173K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (96K) | 129K | (59K) | 319K | (360K) |
| Other Working Capital | 174K | 385K | (777K) | 110K | 339K |
| Other Non-Cash Items | 549K | 752K | 313K | 380K | 129K |
| Operating Cash Flow | (4.94M) | (6.49M) | (6.21M) | (7.34M) | (7.17M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (16.5M) | (22.49M) | (44.41M) | (63.77M) | (44.36M) |
| Sales of Investments | 12.54M | 11.76M | 38.81M | 68.05M | 49.23M |
| Other Investing Activities | 35K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.92M) | (10.73M) | (5.6M) | 4.28M | 4.87M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 31.13M | 0 | 0 | 2.96M | 2.28M |
| Common Stock Repurchased | 0 | 0 | 0 | (6K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 440K | 452K | 366K | 466K | 0 |
| Financing Cash Flow | 31.57M | 452K | 366K | 3.42M | 2.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 22.71M | (16.77M) | (11.45M) | 356K | (27K) |
| Free Cash Flow | (4.94M) | (6.49M) | (6.21M) | (7.34M) | (7.17M) |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.